Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study
Abstract Background The EU gadolinium-based contrast agents (GBCA) market has changed in recent years due to the European Medicines Agency decision to suspend the marketing authorisation of linear GBCA and the marketing authorisation of new generic macrocyclic GBCA. The study aims to understand the...
Main Authors: | Jarl Åsbjørn Jakobsen, Carlo Cosimo Quattrocchi, Frank H. H. Müller, Olivier Outteryck, Andrés Alcázar, Wolfgang Reith, Patricia Fraga, Valeria Panebianco, Alexis Sampedro, Radoslaw Pietura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | BMC Medical Imaging |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12880-021-00600-9 |
Similar Items
-
Toxicity associated with gadolinium-based contrast-enhanced examinations
by: Silvia Maria Lattanzio
Published: (2021-05-01) -
Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications
by: Atiya Fatima, et al.
Published: (2021-09-01) -
Glucosamine Conjugated Gadolinium (III) Oxide Nanoparticles as a Novel Targeted Contrast Agent for Cancer Diagnosis in MRI
by: T Mortezazadeh, et al.
Published: (2020-02-01) -
Gadolinium Deposition in the Brain and Body
by: Aart J. van der Molen
Published: (2019-11-01) -
Non-Cardiogenic Pulmonary Oedema Following the Use of Gadolinium-Based Contrast Medium: A Case Report
by: Nguyen Chilan, et al.
Published: (2020-08-01)